Recent FDA Drug Approvals Rely on Fewer Studies, More Industry Funding - Cancer Therapy Advisor

• The FDA has approved a landmark drug designed to treat pancreatic cancer, one of the deadliest forms of the disease. • The medication utilizes a new therapeutic approach by blocking a specific protein that fuels tumor growth in the vast majority of pancreatic cancer cases.

• The FDA has approved updated COVID-19 vaccines designed to protect against the latest circulating strains of the virus. • Health officials emphasize that these vaccines are most effective at preventing severe disease, hospitalizations, and ICU admissions.

• A new analysis reveals that more than two-thirds of new drugs approved by the FDA in 2024 were sanctioned based on the findings of a single study. • The report indicates a steady decline in the number of studies required for drug approval since 2016, raising concerns about the rigor of the process.

• The U.S. Food and Drug Administration (FDA) has approved a new daily pill developed by Revolution Medicines for the treatment of pancreatic cancer. • This groundbreaking medication introduces a novel therapeutic approach to combat one of the most lethal forms of cancer.

• The U.S. FDA has granted speedy approval to a groundbreaking pancreatic cancer drug developed by Revolution Medicines. • In a large-scale trial, the therapy demonstrated the ability to double the survival rate for patients suffering from advanced, metastatic disease.

• The U.S. has approved daraxonrasib, a breakthrough drug designed to treat pancreatic cancer, which is widely regarded as one of the most serious and difficult-to-treat malignancies. • Unlike traditional chemotherapy, this medication specifically targets the activated KRAS protein found within pancreatic cancer cells to inhibit tumor growth.

• The US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-a-kind oral medication designed to treat the most common form of pancreatic cancer. • Developed by Revolution Medicines, the drug functions as a Ras multiselective inhibitor, targeting specific genetic drivers of the disease.

• The U.S. FDA has approved a supplemental Biologics License Application for Pfizer and BioNTech’s 2026-2027 COVID-19 vaccine formula. • The updated vaccine, COMIRNATY ® XFG, specifically targets the XFG variant to better align with currently circulating strains of the virus.

• Researchers discovered that gut microbes may begin consuming proteins from the protective mucus lining of the gut when their fiber intake is limited. • The study highlights that dietary fiber acts as a critical suppressant to this process, preventing microbes from damaging the intestinal barrier.

• The US Food and Drug Administration (FDA) approved updated Covid-19 vaccines on Thursday to target the dominant XFG variant. • This regulatory decision enables manufacturers to immediately begin shipping the new doses to doctors' offices and pharmacies nationwide.

• A global study published in Nature Health links long-term exposure to air pollutants with millions of cancer cases worldwide, extending beyond known respiratory issues. • Researchers analyzed data from 952 locations between 2000 and 2020, covering a total of 109 million cancer cases to establish these links.